Dieses Maus Monoklonal-Antikörper erkennt spezifisch ErbB2/Her2 (Trastuzumab Biosimilar) in FACS und in vivo. Er zeigt eine Reaktivität gegenüber Human.
Produktnummer ABIN7200659
Kurzübersicht für Rekombinanter ErbB2/Her2 (Trastuzumab Biosimilar) Antikörper (ABIN7200659)
Target
ErbB2/Her2 (Trastuzumab Biosimilar)
Antikörpertyp
Recombinant Antibody
Reaktivität
Human
Wirt
Maus
Klonalität
Monoklonal
Konjugat
Dieser ErbB2/Her2 (Trastuzumab Biosimilar) Antikörper ist unkonjugiert
Applikation
Flow Cytometry (FACS), In vivo Studies (in vivo)
Klon
4D5-8
Verwendungszweck
Trastuzumab Biosimilar, HER2 Monoclonal Antibody
Spezifität
The monoclonal antibody trastuzumab biosimilar specifically binds to the human HER2 / ErbB-2 / c-neu.
Produktmerkmale
Recombinant Humanized IgG1 Monoclonal Antibody.
Aufreinigung
Protein A affinity column
Reinheit
> 95% by SDS-PAGE under reducing conditions and HPLC.
Sterilität
0.2 μm filtered
Endotoxin-Niveau
< 1 EU per 1 mg of the protein by the LAL method.
Immunogen
The monoclonal antibody trastuzumab biosimilar was produced in the trastuzumab biosimilar CHO stable cell line.
Research Grade
Reaktivität: Human
Wirt: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
Applikationshinweise
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by trastuzumab.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
21.2 mg/mL
Buffer
PBS, pH 7.4, no stabilizers or preservatives.
Konservierungsmittel
Without preservative
Handhabung
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Haltbarkeit
12 months
Target
ErbB2/Her2 (Trastuzumab Biosimilar)
Substanzklasse
Biosimilar
Hintergrund
Trastuzumab, a humanized monoclonal antibody, interferes with the HER2/neu receptor and is mainly used to treat certain breast cancers, especially HER2-positive metastatic breast cancer. Combined with chemotherapy, trastuzumab increases both survival and response rate.
There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1; HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, the HER receptors embedded in the cell membrane promote cell growth and division by turning genes on and off. The HER2 pathway stimulates cell proliferation if it normally functions; when HER2 is overexpressed, cell growth accelerates beyond its normal limits, which happens in some cancers, notably certain types of breast cancer.